Hence, further clinical studies are warranted to determine whether early administration of hyperimmunoglobulin therapy can be helpful in patients with severe COVID-19

Hence, further clinical studies are warranted to determine whether early administration of hyperimmunoglobulin therapy can be helpful in patients with severe COVID-19. patients diagnosed with COVID-19 who received the hyperimmunoglobulin concentrate, GC5131, which was produced by the Green Cross Corporation. After the administration of GC5131, five patients died due to an exacerbation of COVID-19 pneumonia. GC5131 was ineffective when administered to critically ill patients with COVID-19. Nevertheless, we propose that to expect a therapeutic effect from GC5131, it should be administered as early as possible to avoid the excessive inflammatory response phase in patients with severe and advanced COVID-19 contamination. This step was difficult to achieve in the real world due to the time required for decision making and the process of the compassionate-use program. Keywords:COVID-19, immunoglobulin, convalescence, plasma, clinical effectiveness == 1. Introduction == It has been hypothesized that the primary cause of the worsening condition of severely ill patients with coronavirus disease 2019 (COVID-19) is usually a (R)-3-Hydroxyisobutyric acid cytokine storm. Dysregulated release of inflammatory products is usually a feature of this disease, leading to organ failure and acute respiratory distress syndrome [1]. Hence, clinical trials on immune-based medications that suppress hyperinflammation are being conducted for their use as a treatment for COVID-19 [2]. Among these medications, administering convalescent plasma (CP), which is usually obtained by extracting blood plasma from donors who have recovered from COVID-19, has been shown (R)-3-Hydroxyisobutyric acid to significantly improve the clinical outcomes of hospitalized patients with the disease [3]. CP provides neutralizing antibodies that stop the viral replication process by blocking the binding of receptors; thus, preventing wall fusion, or preventing the uncoating of viruses once inside the cytoplasm (R)-3-Hydroxyisobutyric acid [4]. Moreover, CP provides passive immunomodulatory mediators, such as anti-inflammatory cytokines, clotting factors, natural antibodies, and other undefined proteins that allow recipients to control excessive inflammatory cascades induced by these (R)-3-Hydroxyisobutyric acid infectious brokers [5]. Both CP and hyperimmunoglobulin therapy are produced from blood plasma. However, highly purified and concentrated specific antibodies are obtained from a number of individuals for hyperimmunoglobulin therapy, which results in high titers of these specific antibodies which are used against a microorganism [6]. As such, hyperimmunoglobulin has a standard and high-titer of antibody, but with less volume when compared with CP. Moreover, the hyperimmunoglobulin material does not include complement proteins, plasma factors, procoagulants, or antifibrinolytics [6]. Furthermore, although some problems exist with the production protocol of using CP, such as a lack of guidelines, lack of donors, and troubles in donor scheduling [7], hyperimmunoglobulin therapy can easily be used because it is usually a formulation already produced by a pharmaceutical organization. In this case, GC5131 is usually a type of hyperimmunoglobulin concentrate produced by the Green Cross Corporation (Yongin-si, Gyeonggi-do, Korea). The Korean Ministry of Food and Drug Security has individually authorized the compassionate use of GC5131 as an unlicensed, investigational therapeutic agent (R)-3-Hydroxyisobutyric acid for critically ill patients with COVID-19 when no other treatments are available [8]. On 23 October 2020, we administered GC5131 as part of the first compassionate-use program in Korea to a critically ill patient who did not respond to other treatments, including dexamethasone and remdesivir. Since then, Rabbit Polyclonal to HSF1 (phospho-Thr142) five more critically ill patients have been treated with GC5131 at our hospital up until 17 December 2020. Few reports exist around the therapeutic efficacy of hyperimmunoglobulin therapy in critically ill patients with COVID-19. Therefore, herein, we statement on six cases of critically ill patients with COVID-19 who received GC5131 as part of a compassionate-use program. == 2. Materials and Methods == This study was conducted at the Kyungpook National University, Chilgok Hospital, a public tertiary hospital in Daegu, Korea. Between 23 October 2020, and 17 December 2020, six patients diagnosed with COVID-19 were administered GC5131, after approval was obtained for the compassionate-use program of GC5131. In the approved cases, the treatment consisted of a single dose of 10,000 mg of GC5131 in a 250 mL answer. The infusion was started at 0.010.02 mL/kg/min for 30 min, after which it was gradually increased to 0.06 for the remainder of the infusion. The electronic medical records of each individual were also examined and analyzed retrospectively. We obtained demographic information, clinical symptoms, and laboratory results, including the management and treatment.